Join C2ST and the Carl R. Woese Institute for Genomic Biology (IGB) for Anticancer Discovery from Pets to People (ACPP), a limited series detailing the latest in cutting-edge research conducted at the University of Illinois Urbana Champaign (Illinois). Learn how the analysis of cancers in pet dogs and cats can help identify promising new anticancer drugs for humans. Dr. Timothy Fan, a veterinary oncologist, and cancer researcher, will walk us through the work being done at the Comparative Oncology Research Laboratory on a subject that has far-reaching implications for the human and animal worlds.
The second program will explore animal case studies.
A central theme of the Comparative Oncology Research Laboratory at Illinois is conducting anticancer research that can benefit both companion animals and human beings. By studying drug delivery strategies in dogs with cancerous tumors, the laboratory can collaborate with scientists and aid in exploring anticancer treatment strategies.
A long-term goal in Dr. Fan’s translational cancer research is to find carryover from what works in pet dogs or cats and translate that to effective treatments for humans. Clinical trials on companion animals diagnosed with cancer have brought new hope to their owners and new data for a cutting-edge cancer drug being developed by scientists at Illinois
Thursday, February 24th, 2022 from 5:00 – 6:00 pm CT, C2ST Facebook Live & C2ST YouTube TV.
Make sure to follow C2ST on Facebook and YouTube to receive notifications when the live program starts.
Use our Q&A app to ask live questions during the program or send in your questions in advance! Remember to upvote your favorite questions.
To support STEM programs like this, you can DONATE to C2ST HERE!
We are dedicated to providing an inclusive environment for everyone. Please respect diversity in individuals and in cultures.
Notice: As a guest of the Chicago Council on Science and Technology (C2ST), you agree to be photographed, videotaped, or filmed and grant C2ST permission to put the finished footage/photography to any uses that it may deem proper including marketing, advertising (print, radio, and television) and PR-related activities.